Tuesday, December 05, 2017 6:24:31 PM
This is not a topic any of the Anavex principals dare even speak of. SEC regulators would jump on any company person making even the slightest claim that Anavex sigma-1 receptors might have wide, expansive applications for a multitude of diseases or conditions, in a diversity of cells, tissues, or organs just yet.
Missling, with his tangential “tip of the ice burg” comment was balancing on the tip of a regulatory deep hole. Dare not go there, implying or intimating truthful but "unproven" things that could affect the share price.
But, nonetheless, could the Anavex technology be far bigger than understood by The Street (retail equity investors), or by others not versed or competent in understanding cellular biology and chemistry? I have training and professional understandings of those topics equivalent to any life science graduate student (if not most PhDs). The answer is, yes.
Yes, sigma-1 receptor sites are known to exist in neurons, on mitochondria. The company freely claims this. There, in the neuron, Anavex 2-73 is able to cause disconnected mitochondria to re-attach to and usefully re-function with adjacent endoplasmic reticula. With this, normal cell function is restored. Inasmuch as most central nervous system diseases involve the mitochondrial dysfunction the Anavex drug restores, it has the potential to effectively treat a number of CNS diseases, including Alzheimer’s, Parkinson’s and others.
Look at the mitochondrial diseases here:
http://mitochondrialdiseases.org/related-diseases/
But sigma-receptors are found in many different tissue types, not just nerves or neurons. There are published indications they affect cardiovascular functions.
Yes, Alzheimer’s and Parkinson’s may well be only the exposed tips of the entire Anavex ice burg. Anavex molecules very likely restore or maintain normal feedback and response interactions (homeostasis) within a host of cells and organs. The Anavex pipeline page (http://www.anavex.com/pipeline/) tells of applications for a number of diseases and conditions. Those listed appear to be the only ones the company presently has strong murine (animal) data on. In more hidden, back of the building labs we can presume that grad students and post-docs are treating any number of rats and mice for a multitude of other diseases and conditions.
In short, the chemical and structural anomalies Anavex 2-73 fixes in neurons exist in other diseases and tissues. Is but a matter of discovering those applications. Such work is surely being done. No need or purpose to pre-maturely announce any of that. Too speculative for SEC rules and Anavex critics. Just do the work. When the time is right, announce new human trials with new Anavex drugs. Complete development of the Anavex technologies will be wide and deep.
Ponder the implications of successful treatment of depression, stroke, pain, and cancer, listed as viable Anavex pipeline targets. Most likely, many more will emerge as murine research continues. The Anavex molecules are an entirely new class of drugs, with yet unknown applications --- probably bigger than antibiotics of the last century. They attacked and solved bacterial infections, one broad class of diseases. Anavex may, in time, uniquely treat a wide diversity of diseases and conditions. New molecules. New science. New medicine. All in continuing development and discovery.
[And, I make no mention of the gigantic potential veterinary applications of Anavex molecules, perhaps supplementing or replacing antibiotics, growth hormones, and other drugs used in animal husbandry.]
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM